4//SEC Filing
Schuetz Thomas J. 4
Accession 0001171843-23-001588
CIK 0001738021other
Filed
Mar 9, 7:00 PM ET
Accepted
Mar 10, 1:34 PM ET
Size
6.2 KB
Accession
0001171843-23-001588
Insider Transaction Report
Form 4
Schuetz Thomas J.
DirectorCHIEF EXECUTIVE OFFICER
Transactions
- Purchase
Common Stock
2023-03-10$3.37/sh+10,000$33,700→ 6,021,873 total
Footnotes (2)
- [F1]The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $3.30 to $3.40 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above.
- [F2]89,051 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 27,937 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 61,114 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 450,000 of the shares represents unvested restricted stock units ("RSU") granted to the reporting person on November 16, 2021. 500,000 of the shares represents unvested restricted stock units ("RSU") granted to the reporting person on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022.
Documents
Issuer
Compass Therapeutics, Inc.
CIK 0001738021
Entity typeother
Related Parties
1- filerCIK 0001591464
Filing Metadata
- Form type
- 4
- Filed
- Mar 9, 7:00 PM ET
- Accepted
- Mar 10, 1:34 PM ET
- Size
- 6.2 KB